The MMRC counts Millennium: The Takeda Oncology Company among its strongest partners. As long-term collaborators, the MMRC and Millennium have worked closely for a number of years, launching 18 trials with Millennium’s compounds through the MMRC’s clinical network. The MMRC’s onsite assistance has ensured speed, quality, and efficiency throughout the drug development process.
In 2012, the MMRC and Millennium joined forces once again to advance the groundbreaking CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) study, a landmark initiative that will radically transform the discovery and development of individualized treatments for the disease. Innovation of this level required the vision of a trusted third party—the MMRC—and a shared commitment to collaborative science from all partners to achieve what single center could execute alone—linking genomic data with clinical data of more than 1000 patients and putting that data in the public domain to enable rapid progress.
“Having new options of therapy is so critical for patients with multiple myeloma. So far this disease is not cured. And until it is, we need new therapies to be able to give patients a chance at that increased survival time, that longer life and, ultimately, those new medicines,” said Deborah Dunsire, MD, President and CEO of Millennium: The Takeda Oncology Company, of her company’s commitment to the CoMMpass study.
The peer-reviewed journal, Personalized Medicine in Oncology, focused on the MMRC’s partnership with Millenium: A Takeda Company in their May, 2012, article. Read more
Deborah Dunsire, MD discusses how the MMRF and the MMRC’s model helps other cancers and other patients across the country. Watch the video here